BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding Re- appointment of M/s Siva Rama Krishna & Associates as Internal Auditor of the Company for FY 2026-27

Balaxi Pharmaceuticals reported mixed financial results for FY2026. Standalone revenue grew 32.6% to Rs. 8,085.11 lakhs with net profit up 42.9% to Rs. 514.69 lakhs. However, consolidated revenue declined 7.7% to Rs. 27,017.35 lakhs with net profit dropping sharply to Rs. 141.69 lakhs from Rs. 2,507.02 lakhs in the prior year, largely due to losses in subsidiary operations (Balaxi Global FZCO and subsidiaries reported losses of Rs. 302.29 lakhs). The Board re-appointed Siva Rama Krishna & Associates as Internal Auditors for FY2026-27 and recommended Ms. Akshita Ostwal as Independent Director for a second 5-year term. Importantly, the company received its Manufacturing Licence for the Jadcherla formulation plant on May 23, 2026, positioning it for commercialization of two products with 40 more in pipeline. Statutory auditors issued unmodified (clean) opinions on both standalone and consolidated financials.